{
  "id": 26080,
  "title": "Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M",
  "url": "https://urgent.news/2026/07/30/pfizers-phase-3-win-for-litfulo-braveheart-attovia-eye-ipos-of-275m",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-07-30T15:16:51.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/pfizers-phase-3-win-for-litfulo-braveheart-attovia-eye-ipos-of-275m-182m/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Pfizer reports Phase 3 wins for Litfulo: The drug succeeded in two trials for active and stable nonsegmental vitiligo, an autoimmune condition that causes skin to progressively lose its color. One ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}